 Chemotherapy invasive thymoma experience patients Stage III IV invasive thymoma men women median age years age chemotherapy Padova Medical Oncology Department All patients regimen cisplatin doxorubicin IV day vincristine IV day cyclophosphamide IV day ADOC monthly intervals life-threatening side effects overall clinical response rate complete response partial response complete remissions Median duration response survival months range months months range months Seven complete remissions subsequent thoracotomy Other chemotherapy combinations radiation therapy second-line treatment minimal responses opinion authors chemotherapy deserves evaluation adjuvant neo-adjuvant treatment invasive and/or inoperable thymoma due high complete response rate overall response rate